Sign in

AURX on OTC

Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. is an American surgical and medical instruments and apparatus company.2 It is headquartered in Gaithersburg, United States.2 Its shares trade on OTC under the symbol AURX.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with IceCure Medical, OSR Health, Inc. or Tenon Medical, Inc., or pick any stock.

  • TickerAURX on OTC2
  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersGaithersburg, United States2
  • Incorporated inDE3
  • Business address8285 El Rio, Suite 190, Houston, Tx 770543
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300H0QI00R4LH8U412
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O COGENCY GLOBAL INC., 19904 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 28908682

See how the biggest companies compare on our leaderboards

Nuo Therapeutics, Inc. is a Delaware corporation organized in 1998 under the name Informatix Holdings, Inc. In 1999, Autologous Wound Therapy, Inc., an Arkansas Corporation, merged with and into Informatix Holdings, Inc. and the name of the surviving corporation was changed to Autologous Wound Therapy, Inc. In 2000, Autologous Wound Therapy, Inc. changed its name to Cytomedix, Inc. (“Cytomedix”). In 2001, Cytomedix, filed for bankruptcy, from which it emerged in 2002 under a Plan of Reorganization.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

66.9%Gross margin5
-76.0%Operating margin5
-75.8%Net margin5
142.7%Revenue growth, 20255
-$1.1MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 67% of the revenue Nuo Therapeutics, Inc. broke down this way in fiscal 2025.

  1. Product$3.1M567%up 126% from 2024
  2. Aurix and Private Label Kits$1.2M627%
  3. License$225.0K75%
  4. Aurix and Private Label Centrifuge Devices$77.0K62%
Products and services by year
Products and services20242025
Product$1.4M$3.1M
Aurix and Private Label Kits$1.2M
License$0$225.0K
Aurix and Private Label Centrifuge Devices$77.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue19¢$1.1M
  • Selling, general and admin81¢$4.7M

Out of $3.3M in revenue.5 The company lost money this year.

Financial statements

Revenue8910115$3.3M in 2025+2167% since 2019
0$1.0M$2.0M$3.0M$4.0M2019: $146.2K$146.2K20192020: $0$020202021: $0$020212022: $112.2K$112.2K20222023: $608.5K$608.5K2023+442%2024: $1.4M$1.4M2024+124%2025: $3.3M$3.3M2025+143%
Gross profit8910115$2.2M in 2025+6927% since 2019
0$1.0M$2.0M$3.0M2019: $31.6K$31.6K20192020: $0$020202021: $0$020212022: $93.0K$93.0K20222023: $482.4K$482.4K2023+419%2024: $1.1M$1.1M2024+120%2025: $2.2M$2.2M2025+109%
Operating income8910115-$2.5M in 2025+160% since 2019
-$4.0M-$3.0M-$2.0M-$1.0M02019: -$969.2K-$969.2K20192020: -$378.1K-$378.1K2020−61%2021: -$90.7K-$90.7K2021−76%2022: -$3.3M-$3.3M2022+3562%2023: -$3.2M-$3.2M2023−5%2024: -$2.5M-$2.5M2024−22%2025: -$2.5M-$2.5M2025+2%
Net income8910115-$2.5M in 2025+110% since 2019
-$4.0M-$3.0M-$2.0M-$1.0M02019: -$1.2M-$1.2M20192020: -$90.9K-$90.9K2020−92%2021: -$90.7K-$90.7K2021−0%2022: -$3.2M-$3.2M2022+3398%2023: -$3.2M-$3.2M2023−0%2024: -$2.3M-$2.3M2024−27%2025: -$2.5M-$2.5M2025+8%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue$3.3M$1.4M
Costs of sales$1.1M$302.8K
Selling, general and administrative$4.7M$3.5M
Total operating expenses$4.7M$3.5M
Loss from operations-$2.5M-$2.5M
us-gaap_GrossProfit$2.2M$1.1M
Interest income (expense), net-$804$105
Gain on settlement of legacy accounts payable obligations$0$133.6K
Other income$5.2K$402
Loss before benefit for income taxes-$2.5M-$2.3M
Net loss-$2.5M-$2.3M
Basic and diluted (in dollars per share)-$0.05-$0.05
Basic and diluted (in shares)47.3M shares45.4M shares

Compare Nuo Therapeutics, Inc. with another company

Corporate structure

Nuo Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Nuo Therapeutics, Inc.

  • Scott M. Pittman Filed SCHEDULE 13D/A on Nuo Therapeutics, Inc., latest Jun 3, 2026 (4 filings since Jul 5, 2022)
  • Paul Anthony Jacobs Filed SCHEDULE 13G/A on Nuo Therapeutics, Inc., latest Feb 12, 2026 (3 filings since Feb 14, 2024)
  • James E. Flynn Filed SC 13G/A on Nuo Therapeutics, Inc., latest Nov 14, 2024 (2 filings since Feb 12, 2024)
  • Charles E. Sheedy Filed SC 13D/A on Nuo Therapeutics, Inc., latest Jul 5, 2022
  • David Emerson Jorden Filed SC 13D on Nuo Therapeutics, Inc., latest Jul 5, 2022
  • Nuo Therapeutics, Inc. Gaithersburg, Maryland, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Nuo Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$884.6K5 Dec 31, 2025$609.9K5 Dec 31, 2024+45.1%
Accumulated depreciation$518.3K5 Dec 31, 2025$432.8K5 Dec 31, 2024+19.7%
Property and equipment, net$366.3K5 Dec 31, 2025$177.0K5 Dec 31, 2024+106.9%
Operating-lease assets (leased space)$99.5K5 Dec 31, 2025$170.9K5 Dec 31, 2024−41.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$548.9K5 Dec 31, 2025$283.7K5 Dec 31, 2024+93.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$213.8K5 Dec 31, 2025$150.4K5 Dec 31, 2024+42.1%
Raw materials$75.0K5 Dec 31, 2025$61.0K5 Dec 31, 2024+23.0%
Finished goods$139.0K5 Dec 31, 2025$89.0K5 Dec 31, 2024+56.2%

Properties, in its own words

Our principal executive offices are located in a leased space at 8285 El Rio Street, Suite 190, Houston, TX 77054.

The Company does not own any real property and does not intend to invest in any real property in the foreseeable future.

Item 2 of the 10-K filed Mar 30, 2026.4

Leadership

Who has led Nuo Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Kshitij Mohan2006–2008
  2. Martin P. Rosendale2008–2014
  3. David Emerson Jorden2016–now

Chief financial officer

  1. Andrew Scott Maslan2006–2012
  2. Steven A. Shallcross2014
  3. David Emerson Jorden2015–now

Chief operating officer

  1. Martin P. Rosendale2008
  2. Peter Clausen2022–now
2010201520202025
Board members and other officers (22)

Former names

  • Nuo Therapeutics, IncNov 13, 2014 to Dec 23, 20143
  • CYTOMEDIX INCAug 14, 2000 to Oct 8, 20143
  • AUTOLOGOUS WOUND THERAPY INCApr 12, 2000 to Apr 10, 20003
  • AUTOLOGOUS WOUND TRERAPY INCDec 10, 1999 to Mar 23, 20003

Timeline

  1. Oct 6, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares41
  2. Aug 17, 20268-K Results of operations42
  3. Jun 3, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares43
  4. May 14, 20268-K Results of operations44
  5. Jan 26, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares45
  6. Dec 17, 20258-K Shareholder vote46
  7. Oct 10, 20258-K Executive or director change; Director nominations; Other events47
  8. May 15, 20258-K Entered a material agreement48
  9. Sep 19, 20248-K Entered a material agreement; Unregistered sale of shares49
  10. Jun 27, 20248-K Other events50
  11. Jun 11, 20248-K Change of auditor51
  12. May 21, 20248-K Entered a material agreement; Unregistered sale of shares52
  13. Jul 29, 2016New chief executive David Emerson Jorden becomes CEO12
  14. Sep 9, 2008New chief executive Martin P. Rosendale becomes CEO13
  15. Aug 18, 2006New chief executive Kshitij Mohan becomes CEO14
  16. Apr 29, 1998Founded Nuo Therapeutics, Inc. is founded2

Calendar

Coming up

  1. Around Nov 20, 2026Next results, estimated About a quarter after its last report. The company hasn't announced the date.

When it reported results

  1. Aug 17, 2026Reported quarterly or annual results42
  2. May 14, 2026Reported quarterly or annual results44

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

140 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 21 major events, 60 insider forms, 11 large holders, 7 private raises, 19 other. The latest 20:

  1. Oct 6, 20264 FORM 4 - SCOTT PITTMAN - SECOND FUNDING WARRANTS EDGAR
  2. Oct 6, 20268-K EDGAR
  3. Aug 31, 20264/A EDGAR
  4. Aug 28, 20264 EDGAR
  5. Aug 17, 20268-K EDGAR
  6. Aug 14, 202610-Q EDGAR
  7. Jul 2, 20264 EDGAR
  8. Jul 2, 20264 EDGAR
  9. Jul 2, 20264 EDGAR
  10. Jul 2, 20264 EDGAR
  11. Jul 2, 20264 EDGAR
  12. Jun 5, 20264 EDGAR
  13. Jun 3, 2026SCHEDULE 13D/A EDGAR
  14. Jun 3, 20268-K EDGAR
  15. Jun 2, 20264 EDGAR
  16. Jun 2, 20264/A EDGAR
  17. May 14, 20268-K EDGAR
  18. May 14, 202610-Q EDGAR
  19. Mar 30, 202610-K EDGAR
  20. Feb 12, 2026SCHEDULE 13G/A EDGAR

The 140 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 8 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 28, 2026JORDEN DAVID EMERSONCEO/CFOBuy7,984$1.09$8.7KForm 4
Aug 27, 2026JORDEN DAVID EMERSONCEO/CFOBuy789$1.07$844Form 4
Nov 28, 2025JORDEN DAVID EMERSONCEO/CFOSale200,000$1.50$300.0KForm 4
Jul 30, 2025SHEEDY CHARLES E10% ownerBuy133,333$1.50$200.0KForm 4
Sep 18, 2024SHEEDY CHARLES E10% ownerBuy125,000$0.75$93.8KForm 4
May 20, 2024SHEEDY CHARLES E10% ownerBuy100,000$0.75$75.0KForm 4
Dec 19, 2023SHEEDY CHARLES E10% ownerBuy150,000$0.50$75.0KForm 4
Aug 1, 2023SHEEDY CHARLES E10% ownerBuy62,500$2.00$125.0KForm 4
Nov 9, 2022JORDEN DAVID EMERSONCEO/CFOSale162,500$1.50$243.8KForm 4
Apr 29, 2022SHEEDY CHARLES E10% ownerBuy804,868$1.00$804.9KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Scott M. PittmanSCHEDULE 13D/A, 4 filings Jul 5, 2022 to Jun 3, 202653
  • Paul Anthony JacobsSCHEDULE 13G/A, 3 filings Feb 14, 2024 to Feb 12, 202654
  • James E. FlynnSC 13G/A, 2 filings Feb 12, 2024 to Nov 14, 202455
  • Charles E. SheedySC 13D/A, 1 filing Jul 5, 202256
  • David Emerson JordenSC 13D, 1 filing Jul 5, 202257

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024David E. Jorden63$225.0K58
2024Peter A. Clausen$210.0K58
2023Chief Executive and$225.0K58
2023Chief Scientific and$225.0K58
2022Operating Officer$210.0K$213.2K58
2022Financial Officer$168.8K$170.5K58

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$8.2M 2022–2025
Money received by yearMoney received by year, 2022–2025: $8.2M in all. Private raises (Form D) $8.2M.$0$1M$2M$3M$4M2022 · Private raises (Form D): $4.0M20222023 · Private raises (Form D): $2.0M20232024 · Private raises (Form D): $1.5M20242025 · Private raises (Form D): $791.4K2025
Figures by year
YearPrivate raises (Form D)Total
2025$791.4K$791.4K
2024$1.5M$1.5M
2023$2.0M$2.0M
2022$4.0M$4.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jul 30, 2025Raised $791,418 in a private offering of equity59 Form D: 9 investors so far Form D
  2. Sep 19, 2024Raised $849,125 in a private offering of equity60 Form D: 10 investors so far Form D
  3. May 20, 2024Raised $650,875 in a private offering of equity61 Form D: 11 investors so far Form D
  4. Dec 19, 2023Raised $962,500 in a private offering of equity62 Form D: 9 investors so far Form D
  5. Aug 1, 2023Raised $1 million in a private offering of equity63 Form D: 9 investors so far Form D
  6. May 18, 2022Raised $407,757 in a private offering of equity64 Form D: 6 investors so far Form D
  7. Apr 29, 2022Raised $3.5 million in a private offering of equity65 Form D: 26 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ancora Advisors LLC4,700$4.3K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Nuo Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNuo Therapeutics, Inc.1
  • CIK0001091596
  • Employer ID (EIN)23-30117024
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address8285 El Rio, Suite 190, Houston, TX 770541
  • Phone832-236-90601
  • Shares outstanding48,433,777 as of Aug 12, 20267
  • Public float$41.1M as of Jun 30, 20254
  • AuditorMaloneBailey, LLP, Houston, Texas PCAOB ID 206; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceDec 10, 19991
  • Filings1,164 in all: 4 (396), 8-K (199), 424B3 (81), 10-Q (57), 3 (38), POS AM (28), EFFECT (25), CORRESP (22)1
    All 57 form types

    DEF 14A (19), 10-K (18), 10QSB (18), UPLOAD (18), 4/A (16), D (16), SC 13D (15), SC 13D/A (13), 10-Q/A (12), 8-K/A (12), NT 10-Q (12), SC 13G/A (12), 5 (10), NT 10-K (10), PRE 14A (10), 10-K/A (8), S-1/A (8), S-3/A (8), SC 13G (8), 10KSB (7), S-1 (7), 424B5 (5), S-3 (5), S-8 (5), 10SB12G/A (4), 3/A (4), REGDEX (4), S-8 POS (4), POS EX (3), SB-2/A (3), DEF 14C (2), DEFA14A (2), RW (2), SB-2 (2), SCHEDULE 13D/A (2), 10QSB/A (1), 10SB12G (1), 25-NSE (1), 8-A12B (1), 8-A12B/A (1), 8-A12G (1), CERTAMX (1), FWP (1), PRE 14C (1), REGDEX/A (1), SC 14D9 (1), SC TO-T (1), SC TO-T/A (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Oct 30, 2025
    Latest 8-K (8-K) Oct 6, 2026

Risk factors and legal proceedings

The risks Nuo Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 40 risks under these headings, as written.4

  • Risks Related to Our Financial Position
  • Our Revenue Base Is Limited to a Single Product Seeking Market Adoption.
  • We May Need Additional Financing and our Ability to Successfully Affect Such Financing Could Be Limited.
  • We Have a Limited Operating History and Limited Operating Experience.
  • Our Financial Position Creates Doubt as to Whether We Will Continue as a Going Concern.
  • We May Issue Additional Equity or Debt Securities Which Will Likely Dilute and May Materially and Adversely Affect the Price of our Common Stock.
  • We May Not Be Able to Timely and Accurately Report our Financial Results or Prevent Fraud If We Are Unable to Maintain Effective Disclosure and Internal Controls.
  • Risks Related to Our Business, Industry and Regulatory Approval of Our Product
  • The Success of Aurix Is Dependent on Acceptance by the Medical Community.
  • The Successful Commercialization of the Aurix System Will Depend on Obtaining Reimbursement from Third-Party Payors.
  • A Disruption in Healthcare Provider Networks Could Have an Adverse Effect on Operations and Profitability.
  • Liquidity Problems or Bankruptcy of our Key Customers or Collaborators Could Have a Significant Adverse Effect on our Business, Financial Condition and Results of Operations.
The other 30 risks
  • We May Be Unable to Attract a Strategic Partner for the Further Development of Potential Future Product Candidates.
  • Our Limited Number of Staff May Affect our Ability to Conduct our Operations and Other Functions Effectively.
  • We Are Substantially Dependent Upon our Executive Officers.
  • We Rely on a Single Supplier for a Reagent Used for Aurix and an Interruption in our Supply Chain for any Reagent of Component Could Have a Material Adverse Effect on our Business.
  • We Could Be Affected by Malpractice or Product Liability Claims.
  • Risks Related to Distribution of Our Aurix Product
  • There Can Be No Assurance that Smith+Nephew Will Be Able to Establish a Market for its Private Label Product.
  • Fulfilling Purchase Orders under the Distribution Agreement Will Place Demands on our Management and Financial Resources.
  • The Existence of a Private Label Alternative to our Aurix Product May Limit the Potential Customers and Sales for our Aurix Product.
  • If Smith+Nephew Determines that Marketing and Sales of its Private Label Product Do Not Meet Its Expectations or Priorities, then Smith+Nephew May Terminate the Distribution Agreement.
  • Our Product Has Existing Competition in the Marketplace and We May Not Be Able to Compete Effectively.
  • Our Efforts to Secure Commercial Partners May Not Be Successful.
  • We May Use Third-Party Collaborators and Service Providers to Help Us Support, Develop or Commercialize our Product Candidates, and our Ability to Commercialize Such Candidates May Be Impaired or Delayed if Such Collaborations or Engagements Are Unsuccessful.
  • If We Are Unable to Maintain and Expand Our Network of Distributors and Sales Agents, We May Not Be Able to Generate Sales.
  • Risks Related to Government Regulations
  • Our Product Is Subject to Governmental Regulation.
  • We Must Comply with the Physician Payment Sunshine Act.
  • Legislative and Administrative Action May Have an Adverse Effect on the Company.
  • Failure to Obtain Regulatory Approval in International Jurisdictions Would Prevent Us from Marketing our Product Abroad.
  • Risks Related to Our Intellectual Property and Cybersecurity
  • Our Intellectual Property Assets Are Critical to our Success.
  • If We Are Unable to Protect the Confidentiality of our Proprietary Information and Know-how, our Competitive Position Would Be Impaired.
  • If We Infringe, or Are Alleged to Infringe, Intellectual Property Rights of Third Parties, our Business Could Be Harmed.
  • Our Business May Be Adversely Impacted by Information Systems Failures or Data Breaches.
  • Data Privacy Security Failures or Breaches Could Expose us to Regulatory and Other Liability.
  • Risks Related to Our Common Stock
  • A Retail Trading Market for our Common Stock May Not Actively Develop.
  • Trading on an Over-the-Counter Market Could Adversely Affect the Liquidity of our Common Stock.
  • U.S. Broker-Dealers May Be Discouraged from Effecting Transactions in Shares of our Common Stock.
  • The Compliance and Reporting Requirements of Being a Public Reporting Company Can Be Time-Consuming and Costly.
  • Our Officers, Directors and Principal Stockholders Can Exert Significant Influence Over Us and May Make Decisions That Are Not in the Best Interests of All Stockholders.
  • Transactions Engaged in by our Officers, Directors or Principal Stockholders Involving our Common Stock May Have an Adverse Effect on the Value of our Common Stock.
  • Volatility of our Stock Price Could Adversely Affect Current and Future Stockholders.
  • Notification, Negotiation, and Participation Rights We Provided to Smith+Nephew May Impact our Ability to License the Aurix Product to or Enter into a Business Combination with a Third Party, or our Ability to Sell Equity Securities during the Term of the Distribution Agreement.

Legal proceedings

There are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition, or cash flows.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
    SEC EDGAROther events
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65